Primary Papillary Serous Carcinoma of the Peritoneum, A Retrospective Analysis of 18 Cases

Authors

  • Taner Turan Ankara Etlik Maternity and Women’s Health Teaching Hospital Gynecologic Oncology Clinic, Ankara
  • Şadıman Altınbaş Ankara Etlik Maternity and Women’s Health Teaching Hospital Gynecologic Oncology Clinic, Ankara
  • Nurettin Boran Ankara Etlik Maternity and Women’s Health Teaching Hospital Gynecologic Oncology Clinic, Ankara
  • Gökhan Tulunay Ankara Etlik Maternity and Women’s Health Teaching Hospital Gynecologic Oncology Clinic, Ankara
  • Reyhan Öcalan Ankara Etlik Maternity and Women’s Health Teaching Hospital Gynecologic Oncology Clinic, Ankara
  • Figen Günday Ankara Etlik Maternity and Women’s Health Teaching Hospital Gynecologic Oncology Clinic, Ankara
  • Deniz Çavuşoğlu Ankara Etlik Maternity and Women’s Health Teaching Hospital Pathology Division, Ankara
  • Faruk Köse Ankara Etlik Maternity and Women’s Health Teaching Hospital Gynecologic Oncology Clinic, Ankara

Keywords:

P rimary Papillary Serous Carcinoma, Peritoneum

Abstract

OBJECTIVE: Primary papillary serous carcinoma of the peritoneum (PPSCP) is an uncommon tumor. The aim of this study was to review of the patients with PPSCP.
STUDY DESIGN: 18 women with PPSCP in gynecologic oncology clinic between 1995 and 2005 were retrospectively reviewed.
RESULTS: At diagnose, one patient (5.5 %) had stage IV and other patients (94.5 %) were IIIC. Six patients received neoadjuvant chemotherapy (paclitaxel/platinum in 5 patients and cyclophosphamide/platinum in the other). Initial or interval optimal/suboptimal debulking surgery was performed in all patients. After surgery, all of the patients received adjuvant chemotherapy including paclitaxel/platinum (n=16) and cyclophosphamide/platinum (n=2). In 6 months after adjuvant chemotherapy, persistent, progressive or recurrence disease was detected in 8 patients (44.4%). In 9 patients (50%) recurrence was detected after 6 months. Clinical complete response to chemotherapy was 55.5%. Survival rate was 90%.
CONCLUSION: PPSPC are frequently indistinguishable from advanced serous papillary carcinoma of the ovary. The treatment choice is optimal cytoreductive surgery with adjuvant chemotherapy, but although the radical treatment is used the survival rate is poor.

Downloads

Download data is not yet available.

Downloads

Published

2006-08-17

How to Cite

1.
Turan T, Altınbaş Şadıman, Boran N, Tulunay G, Öcalan R, Günday F, Çavuşoğlu D, Köse F. Primary Papillary Serous Carcinoma of the Peritoneum, A Retrospective Analysis of 18 Cases. Gynecol Obstet Reprod Med [Internet]. 2006Aug.17 [cited 2024Nov.24];12(2):135-7. Available from: https://gorm.com.tr/index.php/GORM/article/view/586

Issue

Vol. 12 No. 2 (2006)

Section

Gynecology and Gynecological Oncology

License

CC BY

All the articles published in GORM are licensed with "Creative Commons Attribution 4.0 License (CC BY 4.0)". This license entitles all parties to copy, share and redistribute all the articles, data sets, figures and supplementary files published in this journal in data mining, search engines, web sites, blogs and other digital platforms under the condition of providing references.